10x Genomics, Inc. (NASDAQ:TXG) Insider Benjamin J. Hindson Sells 4,573 Shares

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 4,573 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now directly owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

10x Genomics Price Performance

Shares of TXG opened at $11.65 on Thursday. The stock has a 50-day moving average of $14.13 and a 200-day moving average of $16.92. 10x Genomics, Inc. has a one year low of $10.63 and a one year high of $48.42. The company has a market cap of $1.42 billion, a PE ratio of -7.66 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Leerink Partnrs cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. decreased their price target on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Barclays decreased their target price on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Canaccord Genuity Group reduced their target price on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $20.57.

Hedge Funds Weigh In On 10x Genomics

Hedge funds have recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics during the 3rd quarter valued at about $35,000. Blue Trust Inc. boosted its stake in 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after buying an additional 1,025 shares in the last quarter. Signaturefd LLC raised its position in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after purchasing an additional 1,452 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $32,000. Finally, Venturi Wealth Management LLC grew its holdings in shares of 10x Genomics by 1,108.9% in the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after purchasing an additional 2,240 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.